Featured Research

from universities, journals, and other organizations

New antidepressant acts very rapidly and is long lasting

Date:
December 7, 2012
Source:
Northwestern University
Summary:
A first-of-its-kind antidepressant drug now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose. The novel therapeutic targets brain receptors responsible for learning and memory -- a very different approach from existing antidepressants. The new drug could be helpful in treating other neurological conditions.

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

Related Articles


The novel therapeutic targets brain receptors responsible for learning and memory -- a very different approach from existing antidepressants. The new drug and others like it also could be helpful in treating other neurological conditions, including schizophrenia, bipolar disorder, anxiety and Alzheimer's disease.

The results of the phase IIa clinical trial were presented today (Dec. 6) at the 51st Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Fla.

Also this week a paper reporting some of the background scientific research that provided the foundation for the clinical development of GLYX-13 was published by the journal Neuropsychopharmacology.

The compound, called GLYX-13, is the result of more than two decades of work by Joseph Moskal, research professor of biomedical engineering at Northwestern's McCormick School of Engineering and Applied Science and director of the University's Falk Center for Molecular Therapeutics.

"Our study showed that this compound is capable of eliciting a robust and rapid antidepressant effect without the typical side effects seen with other drugs that also modulate the NMDA receptor," said Moskal, who is founder and chief scientific officer of the Evanston-based biotechnology company Naurex Inc., which conducted the clinical study.

GLYX-13 works by modulating the NMDA (N-methyl-D-aspartate) receptor in the brain, as do current NMDA receptor antagonists such as ketamine, but GLYX-13 does not have their serious and limiting side effects, such as hallucinations and schizophrenia-like effects. (An antagonist is a substance that inhibits the physiological action of another.)

Moskal and his team have figured out a new way to target the NMDA receptors that maintains the positive antidepressant properties while eliminating the negative side effects.

In clinical trials administered at 12 sites across the country, a single dose of GLYX-13 resulted in significant reductions in depression symptoms among subjects who had shown little improvement with previous drugs. (Subjects had failed treatment with one or more antidepressant agents.)

The positive effects of GLYX-13 were evident within 24 hours and lasted an average of seven days. The effect size, a measure of the magnitude of the drug's antidepressant efficacy, at both these times after a single dose was nearly double the effect size seen with most other antidepressant drugs after four to six weeks of repeated dosing.

Side effects of GLYX-13 were mild to moderate and were consistent with those observed in subjects receiving a placebo.

GLYX-13 is a four-amino acid peptide that modulates one of a large family of glutamate receptors, the NMDA (N-methyl-D-aspartate) receptor, in the brain. NMDA receptors play a key role in regulating synaptic plasticity -- the quality of the connection between neurons -- and thus are important in regulating learning and memory functions.

GLYX-13 is administered intravenously. Moskal said Naurex also is working on an oral drug with similar properties and potential.

Moskal hopes that these positive GLYX-13 results and the research efforts of his team and colleagues will help shepherd in more research and grant support for studying the role of the glutamate-mediated processes in neuropsychiatric disorders.

"While the results we are seeing with GLYX-13 are very encouraging, I believe the most important research is yet to come," Moskal said. "We have only scratched the surface of the therapeutic potential of the glutamatergic system."

GLYX-13 currently is undergoing a phase IIb clinical trial at 20 sites across the United States. This trial is evaluating repeated doses of the drug.

The Neuropsychopharmacology paper is titled "GLYX-13, an NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects."

The research was supported by grants from the Ralph and Marian Falk Medical Research Trust, the Hope for Depression Research Foundation and the National Institutes of Health (grants MH094835, NS044421 and DA01442).

Northwestern University has exclusively licensed the intellectual property rights related to the therapeutics developed by Joseph Moskal while at the University to Naurex Inc. Northwestern also has a small equity position in Naurex.


Story Source:

The above story is based on materials provided by Northwestern University. The original article was written by Megan Fellman and Sarah Ostman. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jeffrey Burgdorf, Xiao-Lei Zhang, Katherine L Nicholson, Robert L Balster, J David Leander, Patric K Stanton, Amanda L Gross, Roger A Kroes, Joseph R Moskal. GLYX-13, an NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects. Neuropsychopharmacology, 2012; DOI: 10.1038/npp.2012.246

Cite This Page:

Northwestern University. "New antidepressant acts very rapidly and is long lasting." ScienceDaily. ScienceDaily, 7 December 2012. <www.sciencedaily.com/releases/2012/12/121207094604.htm>.
Northwestern University. (2012, December 7). New antidepressant acts very rapidly and is long lasting. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2012/12/121207094604.htm
Northwestern University. "New antidepressant acts very rapidly and is long lasting." ScienceDaily. www.sciencedaily.com/releases/2012/12/121207094604.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Mind & Brain News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Former NFL Players Donate Brains to Science

Former NFL Players Donate Brains to Science

Reuters - US Online Video (Mar. 3, 2015) — Super Bowl champions Sidney Rice and Steve Weatherford donate their brains, post-mortem, to scientific research into repetitive brain trauma. Jillian Kitchener reports. Video provided by Reuters
Powered by NewsLook.com
Alzheimer's Protein Plaque Found In 20-Year-Olds

Alzheimer's Protein Plaque Found In 20-Year-Olds

Newsy (Mar. 3, 2015) — Researchers found an abnormal protein associated with Alzheimer&apos;s disease in the brains of 20-year-olds. Video provided by Newsy
Powered by NewsLook.com
This Nasal Treatment Could Help Ease Migraine Pain

This Nasal Treatment Could Help Ease Migraine Pain

Newsy (Mar. 2, 2015) — Researchers gave lidocaine to 112 patients, and about 88 percent of the subjects said they needed less migraine-relief medicine the next day. Video provided by Newsy
Powered by NewsLook.com
How Facebook Use Can Lead To Depression

How Facebook Use Can Lead To Depression

Newsy (Mar. 1, 2015) — Margaret Duffy of the University of Missouri talks about her study on the social network and the envy and depression that Facebook use can cause. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins